Mouse models of angiogenesis, arterial stenosis, atherosclerosis and hemostasis

Cardiovascular Research

Volumn 39, Issue 1, 1998, Pages 8-33

  Carmeliet, Peter ^a   Moons, Lieve ^a   Collen, Désiré ^a  

^a DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

Author keywords

A denovirus; Angiogenesis; Atherosclerosis; Bleeding; Restenosis; Thrombosis; Transplantation

Indexed keywords

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIOSCLEROSIS; ARTERY OCCLUSION; ATHEROSCLEROSIS; CONTROLLED STUDY; EMBRYO DEVELOPMENT; HEMOSTASIS; HUMAN; MOUSE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; THROMBOSIS;

ANIMALS; CARDIOVASCULAR DISEASES; DISEASE MODELS, ANIMAL; HEMOSTASIS; MICE; MICE, INBRED STRAINS; MICE, MUTANT STRAINS; MICE, TRANSGENIC; NEOVASCULARIZATION, PATHOLOGIC;

EID: 0032127920     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(98)00108-4     Document Type: Review

References (287)

1. [1] Carmeliet P, Collen D. Genetic analysis of blood vessel formation. Role of endothelial versus smooth-muscle cells. Trends Cardiovasc Med 1997;7:271-281.
2. [2] deMello DE, Sawyer D, Galvin N, Reid LM. Early fetal development of lung vasculature. Am J Respir Cell Mol Biol 1997;16:568-581.
3. [3] Hudlicka O, Brown MD. Postnatal growth of the heart and its blood vessels. J Vasc Res 1996;33:266-287.
4. [4] Ment LR, et al. Vascular endothelial growth factor mediates reactive angiogenesis in the postnatal developing brain. Brain Res Dev Brain Res 1997;100:52-61.
5. [5] Wang DB, Blocher NC, Spence ME, Rovainen CM, Woolsey TA. Development and remodeling of cerebral blood vessels and their flow in postnatal mice observed with in vivo videomicroscopy. J Cereb Blood Flow Metab 1992;12:935-946.
6. [6] Stone J, Itin A, Alon T, et al. Development of retinal vasculature is mediated by hypoxia-induced vascular endothelial growth factor (VEGF) expression by neuroglia. J Neurosci 1995;15:4738-4747.
7. [7] Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other diseases. Nature Med 1995;1:27-31.
8. [8] Risau W. Mechanisms of angiogenesis. Nature 1997;386:671-674.
9. [9] Carmeliet P, Collen D. Vascular development and disorders: molecular analysis and pathogenetic insights. Kidney International press 1998;53:in press.
10. [10] Beck L, D'Amore P. Vascular development: cellular and molecular recognition. FASEB 1997;J 11:365-373.
11. [11] Schaper W, Ito WD. Molecular mechanisms of coronary collateral vessel growth. Circ Res 1996;79:911-919.
12. [12] Jain RK, The Eugene M. Landis Award Lecture 1996-Delivery of molecular and cellular medicine to solid tumors. Microcirculation 1997;4:1-23.
13. [13] Jain RK, Schienger K, Höckel M, Yuan F. Quantitative angiogenesis assays: progress and problems. Nat Med 1997;3:1203-1208.
14. [14] Auerbach R, Auerbach W, Polakowski I. Assays for angiogenesis: a review. Pharmacol Ther 1991;51:1-11.
15. [15] Van Maele-Fabry G, Clotman F, Gofflot F, Bosschaert J, Picard JJ. Postimplantation mouse embryos cultured in vitro. Assessment with whole-mount immunostaining and in situ hybridization. Int J Dev Biol 1997;41:365-374.
16. [16] Takakura N, et al. PDGFR alpha expression during mouse embryogenesis: immunolocalization analyzed by whole-mount immunohistostaining using the monoclonal anti-mouse PDGFR alpha antibody APA5. J Histochem Cytochem 1997;45:883-893.
17. [17] Rosen B, Beddington RSP. Whole-mount in situ hybridization in the mouse embryo: gene expression in three dimensions. Trends Genet 1993;9:162-167.
18. [18] Bauer H, et al. Ontogenic expression of the erythroid-type glucose transporter (Glut 1) in the telencephalon of the mouse: correlation to the tightening of the blood-brain barrier. Brain Res Dev Brain Res 1995;86:317-325.
19. [19] Kaipainen A, et al. Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development. Proc Natl Acad Sci USA 1995;92:3566-3570.
20. [20] Fong GH, Rossant J, Gertsenstein M, Breitman ML. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature 1995;376:66-70.
21. [21] Puri MC, Rossant J, Alitalo K, Bernstein A, Partanen J. The receptor tyrosine kinase TIE is required for integrity and survival of vascular endothelial cells. Embo J 1995;14:5884-5891.
22. [22] Shalaby F, et al. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature 1995;376:62-66.
23. [23] Maisonpierre PC, Suri C, Jones PF, et al. Angioprotein-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 1997;277:55-60.
24. [24] Carmeliet P, et al. Role of tissue factor in embryonic blood vessel development. Nature 1996;383:73-75.
25. [25] Rosen E, et al. Factor VII-deficient mice develop normally but suffer fatal perinatal bleeding. Nature 1997;390:290-294.
26. [26] Woo YJ, et al. In utero cardiac gene transfer via intraplacental delivery of recombinant adenovirus. Circulation 1997;96:3561-3569.
27. [27] Carmeliet P, et al. Abnormal blood vessel development and lethality in embryos lacking a single vascular endothelial growth factor allele. Nature 1996;380:435-439.
28. [28] Keller BB, MacLennan MJ, Tinney JP, Yoshigi M. In vivo assessment of embryonic cardiovascular dimensions and function in day 10.5 to 4.5 mouse embryos. Circ Res 1996;79:247-255.
29. [29] Landor M. Maternal-fetal transfer of immunoglobulins. Ann Allergy Asthma Immunol 1995;74:279-284.
30. [30] Letterio JJ, et al. Maternal rescue of transforming growth factor-beta 1 null mice. Science 1994;264:1936-1938.
31. [31] Baldwin HS, Mickanin C, Buck C. Adenovirus-mediated gene transfer during initial organogenesis in the mammalian embryo is promoter-dependent and tissue-specific. Gene Ther 1997;4:1142-1149.
32. [32] Tomanek RJ. Formation of the coronary vasculature: a brief review. Cardiovasc Res 1996;31:E46-E51.
33. [33] Michael LH, et al. Myocardial ischemia and reperfusion: a murine model. Am J Physiol 1995;269:H2147-H2154.
34. [34] Alon T, et al. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat Med 1995;1:1024-1028.
35. [35] Hirschi KK, d'Amore PA. Pericytes in the microvasculature. Cardiovasc Res 1996;32:687-698.
36. [36] D'Amato R, Wesolowski E, Smith LE. Microscopic visualization of the retina by angiography with high-molecular-weight fluorescein-labeled dextrans in the mouse. Microvasc Res 1993;46:135-142.
37. [37] Smith LE, et al. Oxygen-induced retinopathy in the mouse. Invest Ophthalmol Vis Sci 1994;35:101-111.
38. [38] Pierce EA, Avery RL, Foley ED, Aiello LP, Smith LP. Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization. Proc Natl Acad Sci USA 1995;92:905-909.
39. [39] Lang RA. Apoptosis in mammalian eye development: lens morphogenesis, vascular regression and immune privilege. Cell Death Differential 1997;4:12-20.
40. [40] Meeson A, Palmer M, Calfon M, Lang R. A relationship between optosis and flow during programmed capillary regression is revealed by vital analysis. Development 1996;122:3929-3938.
41. [41] Jones R, Reid, L. Vascular remodeling in clinical and experimental pulmonary hypertensions. London: Portland Press, 1995:47-116.
42. [42] Asahara T, et al. Isolation of putative progenitor endothelial cells for giogenesis. Science 1997;275:964-967.
43. [43] Witte MH, Way DL, Witte CL, Bernas M. Lymphangiogenesis: mechanisms, significance and clinical implications. Exs 1997;79:65-112.
44. [44] Kenyon BM, et al. A model of angiogenesis in the mouse cornea. Invest Ophthalmol Vis Sci 1996;37:1625-1632.
45. [45] Kaminska GM, Niederkorn JY. Spontaneous corneal neovascularisation in nude mice. Local imbalance between angiogenic and antiangiogenic factors [see comments]. Invest Ophthalmol Vis Sci 1993;34:222-230.
46. [46] Smith RS, et al. Corn1: a mouse model for corneal surface disease and neovascularization. Invest Ophthalmol Vis Sci 1996;37:397-404.
47. [47] Yuan F, et al. Vascular permeability and microcirculation of gliomas and mammary carcinomas transplanted in rat and mouse cranial windows. Cancer Res 1994;54:4564-4568.
48. [48] Leunig M, et al. Angiogenesis, microvascular architecture, microhemodynamics, and interstitial fluid pressure during early growth of human adenocarcinoma LS174T in SCID mice. Cancer Res 1992;52:6553-6560.
49. [49] Andrade SP, Vieira LBGB, Bakhle YS, Piper PJ. Effects of platelet activating factor (PAF) and other vasoconstrictors on a model of angiogenesis in the mouse. Int J Exp Path 1992;73:503-513.
50. [50] Baatout S, Cheta N. Matrigel: a useful tool to study endothelial differentiation. Rom J Intern Med 1996;34:263-269.
51. [51] Passaniti A, et al. A simple, quantitative method for assessing angiogenesis and antiangiogenic agents using reconstituted basement membrane, heparin, and fibroblast growth factor. Lab Invest 1992;67:519-528.
52. [52] Dellian M, Witwer BP, Salehi HA, Yuan F, Jain RK. Quantitation and physiological characterization of angiogenic vessels in mice. Effects of basic fibroblast growth factor, vascular endothelial growth factor/vascular permeability factor and host microenvironment. Am J Pathol 1996;149:59-71.
53. [53] Norrby K, Jakobsson A, Sorbo J. Quantitative angiogenesis in spreads of intact rat mesenteric windows. Microvasc Res 1990;39:341-348.
54. [54] Thorlacius H, Lindbom L, Raud J. Cytokine-induced leukocyte rolling in mouse cremaster muscle arterioles in P-selectin dependent. Am Physiol 1997;272:1725-1729.
55. [55] Kunkel EJ, et al. Absence of trauma-induced leukocyte rolling in mice deficient in both P-selectin and intercellular adhesion molecule 1. J Med 1996;183:57-65.
56. [56] Brown NJ, Reed MW. Leucocyte interactions with the mouse cremaster muscle microcirculation in vivo in response to tumour-conditioned medium. Br Cancer 1997;75:993-999.
57. [57] Mayrovitz HN. Skin capillary metrics and hemodynamics in the hairless mouse. Microvasc Res 1992;43:46-59.
58. [58] Kamler M, et al. Impact of ischemia on tissue oxygenation and wound healing: intravital microscopic studies on the hairless mouse ear model. Eur Surg Res 1993;25:30-37.
59. [59] Frank JM, et al. Microcirculation research, angiogenesis, and microsurgery. Microsurg 1994;15:399-404.
60. [60] Yuan F, et al. Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. Proc Natl Acad Sci USA 1996;93:14765-14770.
61. [61] Runkel S, Hunter N, Milas L. An intradermal assay for quantification and kinetics studies of tumor angiogenesis in mice. Radiat Res 1991;126:237-243.
62. [62] Brooks PC, et al. Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin [see comments]. J Clin Invest 1995;96:1815-1822.
63. [63] Bonfil RD, et al. Stimulation of angiogenesis as an explanation of Matrigel-enhanced tumorigenicity. Int J Cancer 1994;58:233-239.
64. [64] Okada N, et al. A quantative in vivo method of analyzing human tumor-induced angiogenesis in mice using agarose microencapsulation and hemoglobin enzyme-linked immunosorbent assay. Jpn J Cancer Res 1995;86:1182-1188.
65. [65] Fukumura D, Yuan F, Monsky WL, Chen Y, Jain RK. Effect of host microenvironment on the microcirculation of human colon adenocarcinoma. Am J Pathol 1997;151:679-688.
66. [66] Kandel J, et al. Neovascularization is associated with a switch to the expert of bFGF in the multistep development of fibrosarcoma. Cell 1991;66:1095-1104.
67. [67] Parangi S, et al. Antiangiogenic therapy of transgenic mice impairs de novo tumor growth. Proc Natl Acad Sci USA 1996;93:2002-2007.
68. [68] Greer P, et al. The Fps/Fes protein-tyrosine kinase promotesan angiogenesis in transgenic mice. Mol Cell Biol 1994;14:6755-6763.
69. [69] Dubois Stringfellow N, Kolpack Martindale L, Bautch VL, Azizkhan RG. Mice with hemangiomas induced by transgenic endothial cells. A model for the Kasabach-Merritt syndrome. Am J Pathol 1994;144:796-806.
70. [70] Garlanda C, et al. Progressive growth in immunodeficient mice and host-cell recruitment by mouse endothelial cells transformed by polyoma middle-sized T antigen: implications for the pathogenesis of opportunistic vascular tumors. Proc Natl Acad Sci USA 1994;91:7291-7295.
71. [71] Jacks T. Lessons from the p53 mutant mouse. J Cancer Res Clin Oncol 1996;122:319-327.
72. [72] Neeman M, Abramovitch R, Schiffenbauer YS, Tempel C. Regulation of angiogenesis by hypoxic stress: from solid tumors to the ovarian follicle. Int J Exp Path 1997;78:57-70.
73. [73] Dor Y, Keshet E. Ischemia-driven angiogenesis. Trends Cardiovasc Med 1997;7:289-294.
74. [74] Guyton AC. A concept of negative interstitial pressure based on pressures in implanted perforated capsules. Circ Res 1963;12:399-414.
75. [75] Rivard A, et al. Diabetes impairs angiogenesis in limb ischemia. Circulation (abstract) 1997;96:1-175.
76. [76] Chaplin DJ, Hill SA. Temporal heterogeneity in microregional erythrocyte flux in experimental solid tumors. Br J Cancer 1995;71:1210-1213.
77. [77] Takeshita S, et al. Use of synchrotron radiation microangiography to assess development of small collateral arteries in a rat model of hindlimb ischemia. Circulation 1997;95:805-808.
78. [78] Kern TS, Engerman RL. A mouse model of diabetic retinopathy. Arch Ophthalmol 1996;114:986-990.
79. [79] Berk DA, Swartz MA, Leu AJ, Jain RK. Transport in lymphatic capillaries. II. Microscopic velocity measurement with fluorescence photobleaching. Am J Physiol 1996;270:H330-H337.
80. [80] Jain RK. Delivery of novel therapeutic agents in tumors: physiologic barriers and strategies. J Natl Cancer Inst 1989;81:570-576.
81. [81] McLean JW, et al. Organ-specific endothelial cell uptake of cationic liposome-DNA complexes in mice. Am J Physiol 1997;273:H387-H404.
82. [82] Song YK, Liu D, Maruyama KZ, Takizawa T. Antibody mediated lung targeting of long-circulating emulsions. J Pharm Sci Technol 1996;50:372-377.
83. [83] Huang X, et al. Tumor infarction in mice by antibody-directed targeting tissue factor to tumor vasculature. Science 1997;275:547-550.
84. [84] Weiler Guettler H, Aird WC, Husain M, Rayburn H, Rosenberg RD. Targeting of transgene expression to the vascular endothelium of mice by homologous recombination at the thrombomodulin locus. Circ Res 1996;78:180-187.
85. [85] Varner JA, Brooks PC, Cheresh DA. Review: The integrin αvβ3: angiogenesis and apoptosis. Cell Adhesion Commun 1995;3:367-374.
86. [86] Vittet D, et al. Embryonic stem cells differentiate in vitro to endothelial cells through successive maturation steps. Blood 1996;88:3424-3431.
87. [87] Breier G, et al. Molecular cloning and expression of urine vascular endothelial-cadherin in early stage development of cardiovascular system. Blood 1996;7:630-641.
88. [88] Dumont DJ, et al. Vascularization of the mouse embryo: study of flk-1, tek, tie and vascular endothelial growth factor expression during development. Dev Dyn 1995;203:80-92.
89. [89] Breier G, Clauss M, Risau W. Coordinate expression of vascular endothelial growth factor receptor-1 (flt-1) and its ligand suggests a paracrine regulation of murine vascular development. Dev Dyn 1995;204:228-239.
90. [90] Diaz-Flores L, Gutierrez R, Varela H, Rancel N, Valladares F. Microvascular pericytes: a review of their morphological and functional characteristics. Histol Histopathol 1991;6:269-286.
91. [91] Lindahl P, Johansson BR, Levéen P, Betscholtz C. Pericyte loss and microaneurysm formation in PDGF-BB-deficient mice. Science 1997;277:242-245.
92. [92] Nehls V, Drenckhahn D. The versatility of microvascular perycutes: from mesenchyme to smooth muscle?. Histochemistry 1993;99:1-12.
93. [93] Shepro D, Morel NML. Pericyte physiology. FASEB J 1993;7:1031-1038.
94. [94] Sims DE. Recent advances in pericyte biology - Implications for health and disease. Can J Cardiol 1991;7:431-443.
95. [95] McDonald DM. Endothelial gaps and permeability of venules in rat tracheas exposed to inflammatory stimuli. Am J Physiol 1994;266:L61-L83.
96. [96] McDonald DM. The ultrastructure and permeability of tracheobronchial blood vessels in health and disease. Eur Respir J Suppl 1990;12:572s-585s.
97. [97] Baluk P, et al. Endothelial gaps: time course of formatation and closure in inflamed venules of rats. Am J Physiol 1997;272:L155-L170.
98. [98] Hirata A, Baluk P, Fujiwara T, McDonald DM. Location of focal silver staining at endothelial gaps in inflamed venules examined by scanning electron microscopy. Am J Physiol 1995;269:L403-L418.
99. [99] Nagy JA, et al. Pathogenesis of ascites tumor growth: vascular permeability factor, vascular hyperpermeability, and ascites fluid accumulation. Cancer Res 1995;5:360-368.
100. [100] Thurston G, Baluk P, Hirata A, McDonald DM. Permeability-related changes revealed at endothelial cell borders in inflamed venules by lectin binding. Am J Physiol 1996;271:H2547-H2562.
101. [101] Joris I, DeGirolami U, Wortham K, Majno G. Vascular labelling with monastral blue B. Stain Technol 1982;57:177-183 *LHM: This title is owned by this library *LHC: Mgas, 1982.
102. [102] Perez Atayde AR, et al. Spectrum of tumor angiogenisis in the bone marrow of children with acute lymphoblastic leukemia. Am J Pathol 1997;150:815-821.
103. [103] Hartley CJ, Michael LH, Entman ML. Noninvasive measurements of ascending aortic blood flow velocity in mice. Am J Physiol 1995;268:H499-H505.
104. [104] Abramovitch R, Meir G, Neeman M. Neovascularization induced growth of implanted C6 glioma multicellular spheroids: magnetic resonance microimaging. Cancer Res 1995;55:1956-1962.
105. [105] Wayne Barbee R, Peny BD, Re RN, Murgo JP. Microsphere and dilution techniques for the determination of blood flows and volumes in conscious mice. Am J Physiol 1992;263:R728-R733.
106. [106] Dowell RT, Gairola CG, Diana JN. Reproductive organ blood flow measured using radioactive microspheres in diestrous and estrous mice. Am J Physiol 1992;262:R666-R670.
107. [107] Seo HS, et al. Peripheral vascular stenosis in apoliprotein E-deficient mice. Potential roles of lipid deposition, medial atrophy, and adventitial inflammation. Arterioscler Thromb Vasc Biol 1997;17:3593-3601.
108. [108] Janssen GH, Tangelder GJ, Oude Egbrink MG, Reneman RS. Spontaneous leukocyte rolling in venules in untraumatized skin of conscious and anesthetized animals. Am J Physiol 1994;267:H1119-H1204.
109. [109] Carmeliet P, et al. A model for arterial neointima formation using perivascular electric injury in mice. Am J Pathol 1997;150:761-777.
110. [110] van den Eijnde SM, et al. In situ detection of apoptosis during embryogenesis with annexin V: from whole mount to ultrastructure. Cytometry 1997;29:313-320.
111. [111] Dickson MC, et al. Defective haematopoiesis and vasculogenesis in transforming growth factor-beta 1 knock out mice. Development 1995;121:1845-1854.
112. [112] George EL, Georges Labouesse EN, Patel King RS, Rayburn H, Hynes RO. Defects in mesoderm, neural tube and vascular development in mouse embryos lacking fibronectin. Development 1993;119:1079-1091.
113. [113] Vittet D, Buchou T, Schweitzer A, Dejana E, Huber P. Targeted null-mutation in the vascular endothelial-cadherin gene impairs the organization of vascular-like structures in embryoid bodies. Proc Natl Acad Sci USA 1997;9:6273-6278.
114. [114] Dumont DJ, et al. Dominant-negative and targeted null mutations in endothelial receptor tyrosine kinase, tek, reveal a critical role in vasculogenesis of the embryo. Genes Dev 1994;8:1897-1909.
115. [115] Suri C, et al. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell 1996;87:1171-1180.
116. [116] Wojnowski L, et al. Endothelial apoptosis in Braf-deficient mice [see comments]. Nat Genet 1997;16:293-297.
117. [117] Kozak KR, Abbott B, Hankinson O. ARNT-deficient mice and placental differentiation. Develop Biol 1997;191:247-306.
118. [118] Maltepe E, Schmidt JV, Baunoch D, Bradfield CA, Simon CM. Abnormal angiogenesis and responses to glucose and oxygen deprivation in mice lacking the protein ARNT. Nature 1997;386:403-407.
119. [119] Gnarra JR, et al. Defective placental vasculogenesis causes embryonic lethality in VHL-deficient mice. Proc Natl Acad Sci USA 1997;94:9102-9107.
120. [120] Kwee L, Baldwin S, Stewart C, Buck C, Labow M. Defective development of the embryonic and extraembryonic circulatory system in vascular cell adhesion molecule (VCAM-1)-deficient mice. Development 1995;12:489-503.
121. [121] Yang JT, Rayburn H, Hynes RO. Cell adhesion events mediated by alpha 4 integrins are essential in placental and cardiac development. Development 1995;121:549-560.
122. [122] Kitsukawa T, Shimono A, Kawakami A, Kondoh H, Fujisawa H. Overexpression of a membrane protein, neuropilin, in chimeric mice causes anomalies in the cardiovascular system, nervous system and limbs. Development 1995;121:4309-4318.
123. [123] Soriano P. Abnormal kidney development and hematological disorders in PDGF beta-receptor mutant mice. Genes Dev 1994;8:1888-1896.
124. [124] Kuo CT, et al. The LKLF transcription factor is required for normal tunica media formation and blood vessel stabilization during murine embryogenesis. Genes Dev 1997;11:2996-3006.
125. [125] Löhler J, Timpl R, Jaenisch R. Embryonic lethal mutation in mouse collagen I gene causes rupture of blood vessels and is associated with erythropoietic and mesenchymal cell death. Cell 1984;38:597-607.
126. [126] Prockop DJ. Collagens: molecular biology, disease and potentials for therapy. Annu Rev Biochem 1995;64:403-434.
127. [127] Pereira L, et al. Targeting of the gene encoding fibrillin-1 recapitulates the vascular aspect of Marfan syndrome. Nat Genet 1997;17:218-222.
128. [128] Okamota N, Tobe T, Hackett SF, et al. Transgenic mice with increased expression of vascular endothelial growth factor in the retina. Am J Pathol 1997;151:281-291.
129. [129] Lutty GA, et al. Retinal and choroidal neovascularization in a transgenic mouse model of sickle cell disease. Am J Pathol 1994;145:490-497.
130. [130] Jeltsch M, et al. Hyperplasia of lymphatic vessels in VEGF-C transgenic mice. Science 1997;276:1423-1425.
131. [131] Benjamin LA, Keshet E. Conditional switching of vascular endothelial growth factor (VEGF) expression in tumors: induction of endothelial cell shedding and regression of hemangioblastoma-like vessels by VEGF withdrawal. Proc Natl Acad Sci USA 1997;94:8761-8766.
132. [132] Schwartz SM, Reidy MA, O'Brien ER. Assessment of factors important in atherosclerotic occlusion and restenosis. Thromb Haemost 1995;74:541-551.
133. [133] Libby P, Schwartz D, Brogi E, Tanaka H, Clinton SK. A cascade model for restenosis. A special case of atherosclerosis progression Circulation 1992;6:III47-III52.
134. [134] Clowes AW, Reidy MA, Clowes MM. Mechanisms of stenosis after arterial injury. Lab Invest 1983;49:208-215.
135. [135] Lindner V, Fingerle J, Reidy MA. Mouse model of arterial injury. Circ Res 1993;73:792-796.
136. [136] Carmeliet P, et al. Urokinase-type but not tissue-type 1 plasminogen activator mediates arterial neointima formation in mice. Circ Res 1997;81:829-839.
137. [137] Carmeliet P, et al. Inhibitory role of plasminogen activator inhibitor-1 in arterial wound healing and neointima formation. A gene targeting and gene transfer study in mice. Circulation 1997;96:3180-3191.
138. [138] Sullivan Jr. TR, et al. Estrogen inhibits the response-to-injury in a mouse carotid artery model. J Clin Invest 1995;96:2482-2488.
139. [139] De Geest B, Zhao Z, Collen D, Holvoet P. Effects of adenovirus-mediated human apo A-I gene transfer on neointima formation after endothelial denudation in apo E-deficient mice. Circulation 1997;96:4349-4356.
140. [140] Serrure A, Wither EH, Thomson S, Morris J. Comparison of carbon dioxide laser-assisted anastomosis and conventional microvascular sutured anastomosis. Surg Forum 1986;34:634-636.
141. [141] Kockx MM, Cambier BA, Bortier HE, De Meyer GR, Van Cauwelaert PA. The modulation of smooth-muscle cell phenotype is an early event in human aortocoronary saphenous vein grafts. Virchows Arch A Pathol Anat Histopathol 1992;420:155-162.
142. [142] Douek PC, et al. Dose-dependent smooth-muscle cell proliferation induced by thermal injury with pulsed infrared lasers. Circulation 1992;86:1249-1256.
143. [143] Carmeliet P, Moons L, Ploplis V, Plow EF, Collen D. Impaired arterial neointima formation in mice with disruption of the plasminogen gene. J Clin Invest 1997;99:200-208.
144. [144] Carmeliet P, et al. Receptor-independent role of urokinase-type plasminogen activator in arterial wound healing and intima formation in mice. J Cell Biol 1998;140:233-245.
145. [145] Libby P. Molecular basis of the acute coronary syndromes. Circulation 1995;91:2844-2850.
146. [146] Cowan DB, Langille BL. Cellular and molecular biology of vascular remodeling. Curr Opin Lipidol 1996;7:94-100.
147. [147] Kakuta T, Currier JW, Haudenschild CC, Ryan TJ, Faxon DP. Differences in compensatory vessel enlargement, not intimal formation, account for restenosis after angioplasty in the hypercholesterolemic rabbit model. Circulation 1994;89:2809-2815.
148. [148] Post MJ, Borst C, Pasterkam G, Haudenschild CC. Arterial remodeling in atherosclerosis and restenosis: a vague concept of a distinct phenomenon. Atherosclerosis 1995;118:115-123.
149. [149] Kumar A, Hoover JL, Simmons CA, Lindner V, Shebuski RJ. Remodeling and neointimal formation in the carotid artery of normal and P-selectin-deficient mice. Circulation 1997;96:4333-4342.
150. [150] Bonthu S, Heistad DD, Chappell DA, Lamping KG, Faraci FM. Atherosclerosis, vascular remodeling, and impairment of endothelium-dependent relaxation in genetically altered hyperlipidemic mice. Arterioscler Thromb Vasc Biol 1997;17:2333-2340.
151. [151] Carmeliet P, et al. Urokinase-generated plasmin is a candidate activator of matrix metalloproteinases during atherosclerotic aneurysm formation. Nat Genet 1997;17:439-446.
152. [152] Kockx MM, De Meyer GR, Jacob WA, Bult H, Herman AG. Triphasic sequence of neointimal formation in the cuffed carotid artery of the rabbit. Arterioscler Thromb 1992;12:1447-1457.
153. [153] Moroi M, Gold HK, Yasuda T, Fishman MC, Huang PL. Mice mutant in endothelial nitric oxide synthase: vessel growth and response to injury. Circulation Suppl I 1996;94:154.
154. [154] Umemura K, Watanabe S, Kondo K, Hashimoto H, Nakashima M. Inhibitory effect of prostaglandin E1 on intimal thickening following photochemically induced endothelial injury in the rat femoral artery. Atherosclerosis 1997;130:11-16.
155. [155] Schneider MD, French BA. The advent of adenovirus. Gene therapy for cardiovascular disease. Circulation 1993;88:1937-1942.
156. [156] Rolling F, Nong Z, Pisvin S, Collen D. Adeno-associated virus-mediated gene transfer into rat carotid arteries. Gene Ther 1997;4:757-761.
157. [157] Gibbons GH, Dzau VJ. The emerging concept of vascular remodeling. N Engl J Med 1994;330:143I-1438.
158. [158] Rosenberg RD. Vascular smooth-muscle cell proliferation: basic investigations and new therapeutic approaches. Thromb Haemost 1993;70:10-16.
159. [159] Tsurumi Y, et al. Direct intramuscular gene transfer of naked DNA encoding vascular endothelial growth factor augments collateral development and tissue perfusion [see comments]. Circulation 1996;94:3281-3290.
160. [160] Nabel EG, Pompili VJ, Plautz GE, Nabel GJ. Gene transfer and vascular disease. Cardiovasc Res 1994;28:445-455.
161. [161] Dicheck D, Anderson J, Kelly A, Hanson S, Harker L. Enhanced in vivo antithrombotic effects of endothelial cells expressing recombinant plasminogen activators transduced with retroviral vectors. Circulation 1996;93:301-309.
162. [162] Clowes MM, et al. Long-term biological response of injured rat carotid artery seeded with smooth-muscle cells expressing retrovirally introduced human genes. J Clin Invest 1994;93:644-651.
163. [163] Newman KD, et al. Adenovirus-mediated gene transfer into normal rabbit arteries results in prolonged vascular cell activation, inflammation and neointimal hyperplasia. J Clin Invest 1995;96:2955-2965.
164. [164] Michou AI, et al. Adenovirus-mediated gene transfer: influence of transgene, mouse strain and type of immune response on persistence of transgene expression. Gene Ther 1997;4:473-482.
165. [165] Lijnen R, et al. Plasminogen/plasmin and matrix metalloproteinase system function after vascular injury in mice with targeted inactivation of fibrinolytic genes. Arterioscl Thromb Vasc Biol 1998;in press.
166. [166] Iafrati MD, et al. Estrogen inhibits the vascular injury response in estrogen receptor alpha-deficient mice. Nat Med 1997;3:545-548.
167. [167] Libby P, Tanaka H. The pathogenesis of coronary arteriosclerosis ('chronic rejection') in transplanted hearts. Clin Tranplant 1994;8:313-318.
168. [168] Shi C, Russell ME, Bianchi C, Newell JB, Haber E. Murine model of accelerated transplant arteriosclerosis. Circ Res 1994;75:199-207.
169. [169] Shi C, et al. The immunologic basis of transplant-associated atherosclerosis. Proc Natl Acad Sci USA 1996;93:4051-4056.
170. [170] Shi C, et al. Hypercholesterolemia exacerbates transplant arteriosclerosis via increased neointimal smooth-muscle cell accumulation: studies in apolipoprotein E knockout mice. Circulation 1997;96:2722-2728.
171. [171] Koulack J, et al. Development of a mouse aortic transplant model of chronic rejection. Microsurg 1995;16:110-113.
172. [172] Russel PS, Chase CM, Winn HJ, Colvin RB. Coronary atherosclerosis in transplanted mouse hearts. I. Time course and immunogenetic: and immunopathological considerations. Am J Pathol 1994;144:260-274.
173. [173] Russel P, Chase CM, Winn JJ, Colvin RB. Coronary atherosclerosis in transplanted mouse hearts II. Importance of humoral immunity. J Immunol 1994;152:5135-5141.
174. [174] Russell PS, Chase CM, Colvin RB. Accelerated atheromatous lesions in mouse hearts transplanted to apolipoprotein-E-deficient recipients. Am J Pathol 1996;149:91-99.
175. [175] Russel PS, Chase CM, Winn HJ, Colvin RB. Coronary atherosclerosis in transplanted mouse hearts. III. Effects of recipient treatment with a monoclonal antibody to interferon-gamma. Transplantation 1994;57:1367-1371.
176. [176] Russel PS, Chase CM, Colvin RB. Coronary atherosclerosis in transplanted mouse hearts. IV. Effects of treatment with monoclonal antibodies to intercellular adhesion molecule-1 and leukocyte function-associated antigen-1. Transplantation 1995;60:724-729.
177. [177] Nagano H, et al. Interferon-gamma deficiency prevents coronary arteriosclerosis but not myocardial rejection in transplanted mouse hearts. J Clin Invest 1997;100:550-557.
178. [178] Hirozane T, Matsumori A, Funzkawa Y, Sasayama S. Experimental graft coronary artery disease in a murine heterotopic cardiac transplant model. Circulation 1995;91:386-392.
179. [179] Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993;362:2844-2850.
180. [180] Paigen B, Plump AS, Rubin EM. The mouse as a model for human cardiovascular disease and hyperlipidemia. Curr Opin Lipidol 1994;5:258-264.
181. [181] Plump AS, et al. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell 1992;71:343-353.
182. [182] Zhang SH, Reddick RL, Piedrahita JA, Maeda N. Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science 1992;258:468-471.
183. [183] Nakashima Y, Plump AS, Raines EW, Breslow JL, Ross R. ApoE-deficient mice develop all lesions of all phases of atherosclerosis throughout the arterial tree. Arterioscler Thromb 1994;14:133-140.
184. [184] Reddick RL, Zhang SH, Maeda N. Atherosclerosis in mice lacking ApoE. Evaluation of lesional development and progression. Arterioscler Thromb 1994;14:141-147.
185. [185] van Ree JH, et al. Diet-induced hypercholesterolemia and atherosclerosis in heterozygous apolipoprotein E-deficient mice. Atherosclerosis 1994;111:25-37.
186. [186] Zhang SH, Reddick RL, Burkey B, Maeda N. Diet-induced atherosclerosis in mice heterozygous and homozygous for apolipoprotein E gene disruption. J Clin Invest 1994;94:937-945.
187. [187] Ishibashi S, et al. Hypercholesterolemia in low density lipoprotein receptor knock-out mice and its reversal by adenovirus-mediated gene delivery. J Clin Invest 1993;92:883-893.
188. [188] Ishibashi S, et al. Role of the low-density lipoprotein (LDL) receptor pathway in the metabolism of chylomicron remnants. A quantitative study in knockout mice lacking the LDL receptor, apolipoprotein E, or both. J Biol Chem 1996;271:22422-22427.
189. [189] van Vlijmen BJ, et al. Diet-induced hyperlipoproteinemia and atherosclerosis in apolipoprotein E3-Leiden transgenic mice. J Clin Invest 1994;93:1403-1410.
190. [190] Groot PH, et al. Quantitative assessment of aortic atherosclerosis in APOE*3 Leiden transgenic mice and its relationship to serum cholesterol exposure. Arterioscler Thromb Vasc Biol 1996;16:926-933.
191. [191] Fazio S, et al. Susceptibility to diet-induced atherosclerosis in transgenic mice expressing a dysfunctional human apolipoprotein E(Arg 112,Cysl42). Arterioscler Thromb 1994;14:1873-1879.
192. [192] van Vlijmen BJ, et al. In the absence of endogenous mouse apolipoprotein E, apolipoprotein E*2(Arg-158→Cys) transgenic mice develop more severe hyperlipoproteinemia than apolipoprotein E*3-Leiden transgenic mice. J Biol Chem 1996;271:30595-30602.
193. [193] Warden CH, Hedrick CC, Qiao JH, Castellani LW, Lusis AJ. Atherosclerosis in transgenic mice overexpressing apolipoprotein A-II [published erratum appears in Science 1993 Oct 8;262(5131):164]. Science 1993;261:469-472.
194. [194] Marotti KR, et al. Severe atherosclerosis in transgenic mice expressing simian cholesteryl ester transfer protein. Nature 1993;364:73-75.
195. [195] Vaisman BL, et al. Overexpression of human lecithin cholesterol acyltransferase leads to hyperalphalipoproteinemia in transgenic mice. J Biol Chem 1995;270:12269-12275.
196. [196] Lawn RM, et al. Atherogenesis in transgenic mice expressing human apolipoprotein(a) [see comments]. Nature 1992;360:670-672.
197. [197] Linton MF, et al. Transgenic mice expressing high plasma concentrations of human apolipoprotein B100 and lipoprotein (a). J Clin Invest 1992;92:3029-3037.
198. [198] Paszty C, Maeda N, Verstuyft J, Rubin EM. Apolipoprotein AI transgene corrects apolipoprotein E deficiency-induced atherosclerosis in mice. J Clin Invest 1994;94:899-903.
199. [199] Rubin EM, Krauss RM, Spangler EA, Verstuyft J, Clift SM. Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI. Nature 1991;353:265-267.
200. [200] Plump AS, Scott CJ, Breslow JL. Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse. Proc Natl Acad Sci USA 1994;91:9607-9611.
201. [201] Cohen RD, et al. Reduced aortic lesions and elevated high-density lipoprotein levels in transgenic mice overexpressing mouse apolipoprotein A-IV. J Clin Invest 1997;99:1906-1916.
202. [202] Duverger N, et al. Protection against atherogenesis in mice mediated by human apolipoprotein A-IV. Science 1996;273:966-968.
203. [203] de Silva HV, et al. Overexpression of human apolipoprotein C-III in transgenic mice results in an accumulation of apolipoprotein B48 remnants that is corrected by excess apolipoprotein E. J Biol Chem 1994;269:2324-2335.
204. [204] Masucci Magoulas L, et al. A mouse model with features of familial combined hyperlipidemia. Science 1997;275:391-394.
205. [205] Li H, Reddick RL, Maeda N. Lack of apoA-I is not associated with increased susceptibility to atherosclerosis in mice. Arterioscler Thromb 1993;13:1814-1821.
206. [206] Sakai N, et al. Targeted disruption of the mouse lecithin:cholesterol acyltransferase (LCAT) gene. Generation of a new animal model for human LCAT deficiency. J Biol Chem 1997;272:7506-7510.
207. [207] van Ree JH, et al. Increased response to cholesterol feeding in apolipoprotein C1-deficient mice. Biochem 1995;J 305:905-911.
208. [208] Mezdour H, Jones R, Dengremont C, Castro G, Maeda N. Hepatic lipase deficiency increases plasma cholesterol but reduces susceptibility to atherosclerosis in apolipoprotein E-deficient mice. J Biol Chem 1997;272:13570-13575.
209. [209] Suzuki H, et al. A role for macrophage scavenger receptors in atherosclerosis and susceptibility to infection. Nature 1997;386:292-296.
210. [210] Hirano K, et al. Targeted disruption of the mouse apobec-1 gene abolishes apolipoprotein B mRNA editing and eliminates apolipoprotein B48. J Biol Chem 1996;271:9887-9890.
211. [211] Nakamuta M, et al. Complete phenotypic characterization of apobec-1 knockout mice with a wild-type genetic background and a human apolipoprotein B transgenic background, and restoration of apolipoprotein B mRNA editing by somatic gene transfer of Apobec-1. J Biol Chem 1996;271:25981-25988.
212. [212] Veniant MM, et al. Susceptibility to atherosclerosis in mice expressing exclusively apolipoprotein B48 or apolipoprotein B100. J Clin Invest 1997;100:180-188.
213. [213] Sullivan PM, et al. Targeted replacement of the mouse apolipoprotein E gene with the common human APOE3 allele enhances diet-induced hypercholesterolemia and atherosclerosis. J Biol Chem 1997;272:17972-17980.
214. [214] Boisvert WA, Spangenberg J, Curtiss LK. Treatment of severe hypercholesterolemia in apolipoprotein E-deficient mice by bone marrow transplantation. J Clin Invest 1995;96:1118-1124.
215. [215] Van Eck M, et al. Bone marrow transplantation in apolipoprotein E-deficient mice. Effect of ApoE gene dosage on serum lipid concentrations, (beta)VLDL catabolism, and atherosclerosis. Arterioscler Thromb Vasc Biol 1997;17:3117-3126.
216. [216] Linton MF, Atkinson JB, Fazio S. Prevention of atherosclerosis in apolipoprotein E-deficient mice by bone marrow transplantation. Science 1995;267:1034-1037.
217. [217] Shimano H, et al. Inhibition of diet-induced atheroma formation in transgenic mice expressing apolipoprotein E in the arterial wall. J Clin Invest 1995;95:469-476.
218. [218] Kashyap VS, et al. Apolipoprotein E deficiency in mice: gene replacement and prevention of atherosclerosis using adenovirus vectors. J Clin Invest 1995;96:1612-1620.
219. [219] Tsukamoto K, Smith P, Glick JM, Rader DJ. Liver-directed gene transfer and prolonged expression of three major human ApoE isoforms in ApoE-deficient mice. J Clin Invest 1997;100:107-114.
220. [220] Tsukamoto K, et al. Comparison of human apoA-I expression in mouse models of atherosclerosis after gene transfer using a second generation adenovirus. J Lipid Res 1997;38:1869-1876.
221. [221] Qiao JH, Fishbein MD, Demer LL, Lusis AJ. Genetic determination of cartilaginous metaplasia in mouse aorta. Arterioscler Thromb Vasc Biol 1995;15:2265-2272.
222. [222] Qiao J-H, et al. Pathology of atheromatous lesions in inbred and genetically engineered mice. Genetic determination of arterial calcification. Arterioscler Thromb 1994;14:1480-1497.
223. [223] Luo G, et al. Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature 1997;386:78-81.
224. [224] Qiao JH, et al. Role of macrophage colony-stimulating factor in atherosclerosis: studies of osteopetrotic mice. Am J Pathol 1997;150:1687-1699.
225. [225] Xiao Q, et al. Plasminogen deficiency accelerates vessel wall disease in mice predisposed to atherosclerosis. Proc Natl Acad Sci USA 1997;94:10335-10340.
226. [226] Patel MI, Hardman DT, Fisher CM, Appleberg M. Current views on the pathogenesis of abdominal aortic aneurysms. J Am Coll Surg 1995;181:371-382.
227. [227] Halloran BG, Baxter BT. Pathogenesis of aneurysms. Semin Vasc Surg 1995;8:85-92.
228. [228] Lichtman AH, Cybulsky M, Luscinskas FW. Immunology of atherosclerosis: the promise of mouse models [comment]. Am J Pathol 1996;149:351-357.
229. [229] Emeson EE, Shen ML, Bell CGH, Qureshi A. Inhibition of atherosclerosis in CD4 T-cell-ablated and nude (nu/nu) CS7BL/6 hyperlipidemic mice. Am J Pathol 1996;149:675-685.
230. [230] Fyfe AI, Qiao JH, Lusis AJ. Immune-deficient mice develop typical atherosclerotic fatty streaks when fed an atherogenic diet. J Clin Invest 1994;94:2516-2520.
231. [231] Daugherty A, et al. The effects of total lymphocyte deficiency on the extent of atherosclerosis in apolipoprotein E - / - mice. J Clin Invest 1997;100:1575-1580.
232. [232] Dansky HM, Charlton SA, Harper MM, Smith JD. T and B lymphocytes play a minor role in atherosclerotic plaque formation in the apolipoprotein E-deficient mouse. Proc Natl Acad Sci USA 1997;94:4642-4646.
233. [233] Gupta S, et al. IFN-gamma potentiates atherosclerosis in ApoE knock-out mice. J Clin Invest 1997;99:2752-2761.
234. [234] Smith JD, et al. Decreased atherosclerosis in mice deficient in both macrophage colony-stimulating factor (op) and apolipoprotein E. Proc Natl Acad Sci USA 1995;92:8264-8268.
235. [235] Schreyer SA, Peschon JJ, LeBoeuf RC. Accelerated atherosclerosis in mice lacking tumor necrosis factor receptor p55. J Biol Chem 1996;271:26174-26178.
236. [236] Nishina PM, Naggert JK, Verstuyft J, Paigen B. Atherosclerosis in genetically obese mice: the mutants obese, diabetes, fat, tubby and lethal yellow. Metabolism 1994;43:554-558.
237. [237] Emeson EE, Manaves V, Singer T, Tabesh M. Chronic alcohol feeding inhibits atherogenesis in CS7BL/6 hyperlipidemic mice. Am J Pathol 1995;147:1749-1758.
238. [238] Lee KJ, et al. A murine model of accelerated atherosclerosis in diabetic LDL receptor-deficient mice [abstract]. Circulation 1997;96:1-175.
239. [239] Park L, et al. A murine model of accelerated diabetic atherosclerosis: suppression by soluble receptor for advanced glycation endproducts [abstract]. Circulation 1997;96:1-550.
240. [240] Paigen B, Morrow A, Holmes PA, Mitchell D, Williams RA. Quantitative assessment of atherosclerotic lesions in mice. Atherosclerosis 1987;68:231-240.
241. [241] Purcell Huynh DA, et al. Transgenic mice expressing high levels of human apolipoprotein B develop severe atherosclerotic lesions in response to a high-fat diet. J Clin Invest 1995;95:2246-2257.
242. [242] Palinski W, et al. ApoE-deficient mice are a model of lipoprotein oxidation in atherogenesis. Demonstration of oxidation-specific epitopes in lesions and high titers of autoantibodies to malondial-dehyde-lysine in serum. Arterioscler Thromb 1994;14:605-616.
243. [243] Tangirala RK, Rubin EM, Palinski W. Quantitation of atherosclerosis in murine models: correlation between lesions in the aortic origin and in the entire aorta, and differences in the extent of lesions between sexes in LDL receptor-deficient and apolipoprotein E-deficient mice. J Lipid Res 1995;36:2320-2328.
244. [244] Daley SJ, Herderick EE, Cornhill JF, Rogers KA. Cholesterol-fed and casein-fed rabbit models of atherosclerosis. Part I: Differing lesion area and volume despite equal plasma cholesterol levels. Arterioscler Thromb 1994;14:95-104.
245. [245] Daugherty A, Zweifel BS, Schonfeld G. The effects of probucol on the progression of atherosclerosis in mature Watanabe heritable hyperlipidaemic rabbits. Br J Pharmacol 1991;103:1013-1018.
246. [246] Collen D, Lijnen HR. Basic and clinical aspects of fibrinolysis and thrombolysis. Blood 1991;78:3114-3124.
247. [247] Davie EW. Biochemical and molecular aspects of the coagulation cascade. Thromb Haemost 1995;74:1-6.
248. [248] Kumada T, Dittman WA, Majerus PW A role for thrombomodulin in the pathogenesis of thrombin-induced thromboembolism in mice. Blood 1988;71:728-733.
249. [249] Roba J, Claeys M, Lambelin G. Antiplatelet and antithrombogenic effects of suloctidil. Eur J Pharmacol 1976;37:265-274.
250. [250] DiMinno G, Silver MJ. Mouse antithrombotic assay: a simple method for the evaluation of antithrombotic agents in vivo. Potential of antithrombotic activity by ethyl alcohol. J Pharmacol Exp Ther 1983;225:57-60.
251. [251] Beviglia L, et al. Mouse antithrombotic assay. Inhibition of platelet thromboembolism by disintegrins. Thromb Res 1993;71:301-315.
252. [252] Guarneri L, et al. A new model of pulmonary microembolism in the mouse. J Pharmacol Methods 1988;20:161-167.
253. [253] Farrehi PM, Ozaki CK, Carmeliet P, Fay WP. Regulation of arterial thrombolysis by plasminogen activator inhibitor-I in mice. J Clin Invest 1998;97:1002-1008.
254. [254] Menezes da Silva FA, Newman EL. Dynamic capillaroscopy: a minimally invasive technique for assessing photodynamic effects in vivo. Photochem Photobiol 1993;58:884-889.
255. [255] Matsuno H, Uematsu T, Nagashima S, Nakashima M. Photochemically induced thrombosis model in rat femoral artery and evaluation of effects of heparin and tissue-type plasminogen activator with the use of this model. J Pharmacol Methods 1991;25:303-317.
256. [256] Pierangeli SS, Harris EN. Antiphospholipid antibodies in an in vivo thrombosis model in mice. Lupus 1994;3:247-251.
257. [257] Laux V, Seiffge D. Platelet function in the dorsal skin fold chamber of the rat. In Vivo 1993;7:45-51.
258. [258] Yamamoto K, Loskutoff DJ. Fibrin deposition in tissues from endotoxin-treated mice correlates with decreases in the expression of urokinase-type but not tissue-type plasminogen activator. J Clin Invest 1996;97:2440-2451.
259. [259] Carmeliet P, et al. Physiological consequences of loss of plasminogen activator gene function in zn mice. Nature 1994;368:419-424.
260. [260] Carmeliet P, et al. Plasminogen activator inhibitor-I gene-deficient mice. II. Effects on hemostasis, thrombosis and thrombolysis. J Clin Invest 1993;92:2756-2760.
261. [261] Barazzone C, Belin D, Piguet PF, Vassalli JD, Sappino AP. Plasminogen activator inhibitor-I in acute hyperoxic mouse lung injury. J Clin Invest 1996;98:2666-2673.
262. [262] Lawson CA, et al. Monocytes and tissue factor promote thrombosis in a murine model of oxygen deprivation. J Clin Invest 1997;99:1729-1738.
263. [263] Pinsky DJ et al. Hypoxia-mediated suppression of fibrinolysis enhances pulmonary vascular fibrin deposition. J Clin Invest 1998;in press.
264. [264] el Sabban F, Fahim MA. Local cerebral hyperthermia induces spontaneous thrombosis and arteriolar constriction in the pia mater of the mouse. Int J Biometeorol 1995;38:92-97.
265. [265] De Paepe ME, Trudel M. The transgenic SAD mouse: a model of human sickle cell glomerulopathy. Kidney Int 1994;46:1337-1345.
266. [266] Adachi Y, et al. Effect of bone marrow transplantation on antiphospholipid antibody syndrome in murine Lupus mice. Immunobiol 1995;192:218-230.
267. [267] Olee T, et al. A monoclonal IgG anticardiolipin antibody from a patient with the antiphospholipid syndrome is thrombogenic in mice. Proc Natl Acad Sci USA 1996;93:8606-8611.
268. [268] Ploplis VA, et al. Effects of disruption of the plasminogen gene on thrombosis, growth and health in mice. Circulation 1995;92:2585-2593.
269. [269] Huang ZF, Higuchi D, Lasky N, Broze GJJ. Tissue factor pathway inhibitor gene disruption produces intrauterine lethality in mice. Blood 1997;90:944-951.
270. [270] Cui J, Saunders TL, Ginsburg D. Analysis of factor V function by gene targeting in embryonic stem cells. Blood 1995;86:449a.
271. [271] Palabrica TM, et al. Antiflbrinolytic activity of apolipoprotein(a) in vivo: human apolipoprotein(a) transgenic mice are resistant to tissue plasminogen activator-mediated thrombolysis [published erratum appears in Nat Med 1995 Jun;1(6):598]. Nat Med 1995;1:256-259.
272. [272] Carmeliet P, Stassen JM, Meidell R, Collen D, Gerard R. Adenovirus-mediated gene transfer of rt-PA restores thrombolysis in t-PA-deficient mice. Blood 1997;90:1527-1534.
273. [273] Dejana E, Callioni A, Quintana A, de Gaetano G. Bleeding time in laboratory animals. II A comparison of different assay conditions in rats. Thromb Res 1979;15:191-197.
274. [274] Novak EK, et al. Cocoa: a new mouse model for platelet storage pool deficiency. Br J Haematol 1988;69:371-378.
275. [275] Cui J, O'Shea KS, Purkayastha A, Saunders TL, Ginsburg D. Fatal haemorrhage and incomplete block to embryogenesis in mice lacking coagulation factor V. Nature 1996;384:66-68.
276. [276] Suh TT, et al. Resolution of spontaneous bleeding events but failure of pregnancy in fibrinogen-deficient mice. Genes Dev 1995;9:2020-2033.
277. [277] Shivdasani RA, et al. Transcription factor NF-E2 is required for platelet formation independent of the actions of thrombopoietin/ MGDF in megakaryocyte development. Cell 1995;81:695-704.
278. [278] Bi L, et al. Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A. Nat Genet 1995;10:119-121.
279. [279] Wang L, et al. A factor IX-deficient mouse model for hemophilia B gene therapy. Proc Natl Acad Sci USA 1997;94:11563-11566.
280. [280] Kung SH, et al. Human factor IX corrects the bleeding diathesis of mice with hemophilia B. Blood 1998;91:784-790.
281. [281] Nichols WC, et al. von Willebrand disease in the RIIIS/J mouse is caused by a defect outside of the von Willebrand factor gene. Blood 1995;86:2461.
282. [282] Rusiniak ME, et al. Molecular markers near the mouse brachymorphic (bm) gene, which affects connective tissues and bleeding time. Mamm Genome 1996;7:98-102.
283. [283] Swank RT, Reddington M, Novak EK. Inherited prolonged bleeding time and platelet storage-pool deficiency in the subtle gray (sut) mouse. Lab Anim Sci 1996;46:56-60.
284. [284] Oberhauser AF, Fernandez JM. A fusion pore phenotype in mast cells of the ruby-eye mouse. Proc Natl Acad Sci USA 1996;93:14349-14354.
285. [285] Swank RT, Sweet HO, Davisson MT, Reddington M, Novak EK. Sandy: a new mouse model for platelet storage pool deficiency. Genet Res 1991;58:51-62.
286. [286] Turecek PL, et al. Assessment of bleeding for the evaluation of therapeutic preparations in small animal models of antibody-induced hemophilia and von Willebrand disease. Thromb Haemost 1997;77:591-599.
287. [287] Snyder RO, et al. Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors. Nat Genet 1997;16:270-276.